Patient Safety First: Ethics Committees and IRBs Explained
Introduction: The Independent Voice for Every Trial Participant
Before a single patient is enrolled in a
clinical trial, before the first dose of an investigational drug is
administered, and before the first informed consent form is signed — the trial
must receive approval from an independent body charged with reviewing its
scientific and ethical justification. That body is the Ethics Committee — known
in the United States as the Institutional Review Board — and its oversight role
is among the most important safeguards built into the clinical research system.
For students completing a Clinical
Research Course in Pune, understanding how Ethics Committees function,
what they review, and how they interact with sponsors and investigators is
essential knowledge for every role in clinical trial conduct.
What is an Ethics Committee?
An Ethics Committee is an independent body
composed of medical and non-medical professionals — including physicians,
scientists, lawyers, patient advocates, and community representatives — whose
purpose is to ensure that clinical trials are ethically acceptable,
scientifically sound, and conducted in a manner that protects participant
rights and wellbeing. In India, Ethics Committees must be registered with CDSCO
and comply with the New Drugs and Clinical Trials Rules 2019, Schedule Y, and
the ICMR ethical guidelines for biomedical research.
What Does an Ethics Committee Review?
Before approving a trial, an Ethics Committee
conducts a comprehensive review of the documentation package. Clinical
Research Institute in Pune that
train students in site management and GCP compliance dedicate specific
curriculum time to what constitutes an EC submission — because preparing and
tracking EC applications is a core responsibility for Clinical Research
Coordinators and site-based research staff. The review package typically
includes:
•
The clinical trial protocol — including study
rationale, design, eligibility criteria, and statistical plan
•
The Investigator's Brochure — summarising preclinical and
available clinical data on the investigational product
•
The informed consent form — assessed for completeness,
readability, and GCP compliance
•
Investigator qualifications, site facilities, and
insurance and compensation arrangements for trial-related injury
Ongoing Oversight: ECs Don't Just Approve — They Monitor
EC oversight does not end at trial approval.
Throughout the study, the Ethics Committee must receive and review protocol
amendments, all serious adverse events occurring at the site, annual progress
reports, and any safety information that may materially affect the benefit-risk
assessment. The requirement to report serious adverse events to the EC within
14 days under Indian regulations creates a direct link between the trial's
pharmacovigilance activities and its ethical oversight — reinforcing the
connection between safety reporting and ethical accountability that every site
professional must understand.
Ethics Committees and Pharmacovigilance
The relationship between Ethics Committees
and pharmacovigilance is more direct than many early-career professionals
realise. When a SUSAR is identified during a clinical trial, it must be
reported not only to the regulatory authority and sponsor but also to the
site's Ethics Committee — which has the authority to suspend or terminate the
trial if it concludes that the safety profile makes continued participation
unacceptably risky. This gives the EC a de facto pharmacovigilance function at
the site level, making an understanding of EC oversight directly relevant to
every student completing a Pharmacovigilance
Course in Pune who intends to work in clinical trial safety.
IRBs: The US Equivalent
In the United States, the Institutional
Review Board serves the same fundamental purpose as the Ethics Committee — independent
ethical review and ongoing oversight of human subjects research — but operates
under FDA regulations (21 CFR Parts 56 and 312). For Indian professionals
working on global trials that include US sites, understanding IRB requirements
alongside EC obligations provides the regulatory breadth that multinational CRO
employers value highly.
Conclusion: Ethics is Everyone's Responsibility
Ethics Committees and IRBs exist because the
history of clinical research includes episodes where patient safety was subordinated
to scientific or commercial interests — with devastating consequences. Their
independent oversight role is not a bureaucratic obstacle; it is a fundamental
protection that every clinical research professional should understand,
respect, and actively support.
Comments
Post a Comment